Anxiety disorders are twice as common in women as in men, and the hormonal fluctuations of the menstrual cycle, perimenopause, and menopause are significant contributing factors. Selank — a synthetic analog of the endogenous peptide tuftsin — offers a novel mechanism for addressing anxiety and mood disruption that is particularly relevant to female hormonal biology.
The GABA-Modulating Mechanism
Selank exerts its anxiolytic effects primarily through modulation of the GABAergic system — the same system targeted by benzodiazepines, but without the sedation, tolerance, or dependence associated with those drugs. It also upregulates the expression of BDNF (brain-derived neurotrophic factor), which supports neuroplasticity and mood regulation.
PMS and PMDD
Premenstrual syndrome (PMS) and its more severe form, PMDD (premenstrual dysphoric disorder), are characterized by anxiety, irritability, mood swings, and cognitive difficulties in the luteal phase of the menstrual cycle. These symptoms are driven by the neurological effects of progesterone metabolites (particularly allopregnanolone) on GABA receptors. Selank's GABAergic modulation may directly address this mechanism.
Perimenopause and Anxiety
The hormonal volatility of perimenopause — characterized by erratic estrogen fluctuations before the final decline — is a major driver of anxiety in midlife women. Estrogen has direct effects on serotonin and GABA systems, and its decline disrupts these neurotransmitter systems. Selank's anxiolytic effects provide a non-hormonal approach to managing this transition.